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Therapeutic treatment for systemic mycoses is severely hampered by the extremely limited number of antifungals. The difficulty
of treatment of fungal infections in the central nervous system is further compounded by the poor central nervous system (CNS)
penetration of most antifungals due to the blood-brain barrier. Only a few fungistatic azole drugs, such as fluconazole, show rea-
sonable CNS penetration. Here we demonstrate that sertraline (Zoloft), the most frequently prescribed antidepressant, displays
potent antifungal activity against Cryptococcus neoformans, the major causative agent of fungal meningitis. In in vitro assays,
this neurotropic drug is fungicidal to all natural Cryptococcus isolates tested at clinically relevant concentrations. Furthermore,
sertraline interacts synergistically or additively with fluconazole against Cryptococcus. Importantly, consistent with our in vitro
observations, sertraline used alone reduces the brain fungal burden at an efficacy comparable to that of fluconazole in a murine
model of systemic cryptococcosis. It works synergistically with fluconazole in reducing the fungal burden in brain, kidney, and
spleen. In contrast to its potency against Cryptococcus, sertraline is less effective against strains of Candida species and its inter-
actions with fluconazole against Candida strains are often antagonistic. Therefore, our data suggest the unique application of
sertraline against cryptococcosis. To understand the antifungal mechanisms of sertraline, we screened a whole-genome deletion
collection of Saccharomyces cerevisiae for altered sertraline susceptibility. Gene ontology analyses of selected mutations suggest
that sertraline perturbs translation. In vitro translation assays using fungal cell extracts show that sertraline inhibits protein
synthesis. Taken together, our findings indicate the potential of adopting this antidepressant in treating cryptococcal meningitis.
Systemic fungal infections have increased dramatically world-wide during the past 3 decades due to the growing immuno-
compromised population, resulting from organ and tissue trans-
plantation, cancer therapy, steroid therapy, and HIV infection (2,
18).Cryptococcus neoformans, one of themajor opportunistic fun-
gal pathogens, can cause systemic infections that commonly in-
volve the central nervous system (CNS) (5, 18). Cryptococcal
meningitis is always fatal without treatment. Approximately 25%
to 30%ofAIDSpatientsworldwide (0.6million) die each year as
a consequence of this disease (24). The serious threat caused by
Cryptococcus is further exacerbated by the limitations of the cur-
rent antifungal therapy for treatment of cryptococcosis.
The available repertoire of antifungals against Cryptococcus, as
well as other fungal pathogens, is extremely limited in number.
The newly developed echinocandins that target fungal -1,3-glu-
can synthase are promising in treating infections caused byAsper-
gillus and Candida species, but they are ineffective against Crypto-
coccus species (17). The standard treatment for AIDS-related
cryptococcal meningitis still relies on a 2-week induction treat-
ment with amphotericin B (or liposomal amphotericin B), fol-
lowed by consolidation and lifelong maintenance therapy with
azole drugs, especially fluconazole (FLC) (26). Amphotericin B
was discovered in the 1950s, and its use is limited to the initial
treatment due to its toxicity (11, 26). Fluconazole is well tolerated
by patients and shows good penetration into the CNS (3). How-
ever, fluconazole is fungistatic rather than fungicidal (9). Because
fungal infections of the brain have poor prognoses (5) and because
negative brain cultures are not always achievable with current an-
ticryptococcosis therapy (4), it is critical to develop antifungals
that can penetrate the CNS and clear the brain fungal burden.
Given the challenges of de novo antifungal drug development,
identification of existing clinical compounds that exert fungicidal
activity represents a reasonable approach to improve current an-
tifungal treatment. During our previous screen of the Johns Hop-
kins Clinical Compound Library (40), we identified a modest
growth-inhibitory effect of sertraline (SRT) against the filamen-
tous fungus Aspergillus nidulans. Potential antifungal activity of
this antidepressant was first observed in a clinical setting: three
patients with premenstrual dysphoric disorder (PMDD) and re-
current vulvovaginal candidiasis (VVC) were treated with sertra-
line for their PMDD.Their clinical symptomsofVVCdisappeared
during the sertraline therapy but recurred after treatment was
stopped (13). Follow-up in vitro studies demonstrated that sertra-
line is fungicidal againstAspergillus andCandida, withMICs rang-
ing from 7 to256g/ml (12, 13). Because theMICs of sertraline
against theseAspergillus andCandida strains aremuchhigher than
the serum concentrations of sertraline (55 to 250 ng/ml) achiev-
able in standard therapeutic regimens (34), the potential clinical
value of sertraline in treating systemic infections caused by these
fungi was considered low (37).
The data presented in this report demonstrate that sertraline is
particularly potent against Cryptococcus, with its fungicidal con-
centrations falling below 10 g/ml. Furthermore, previous phar-
macokinetics studies of sertraline in rats and dogs indicate that
sertraline concentrations in cerebrospinal fluid, brain, and some
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other organs are 20- to 40-fold higher than its serum concentra-
tion (31). Such levels could meet or exceed the MICs of sertraline
against Cryptococcus isolates. In addition, abundant clinical data
support the safety of long-term use of this antidepressant (6, 28,
29). Given its psychotropic nature and its potent fungicidal activ-
ity against Cryptococcus, we hypothesized that sertraline could be
uniquely suitable in treating systemic cryptococcosis.
The mechanism of action of sertraline in the mammalian ner-
vous system has been well characterized: it blocks the 5-hydroxy-
tryptamine (5-HT) transporter and inhibits the reuptake of 5-HT
into the presynaptic cell (1). However, there is no conserved ho-
molog of the 5-HT transporter in fungi. Thus, the underlying
mechanisms responsible for the antifungal activity of sertraline
remain mysterious. One report attributed the antifungal activity
of sertraline to a nonspecific cytotoxicity due to its lipophilicity
(37). However, findings of two recent studies suggested mem-
brane organization and vesicle-mediated transport as its antifun-
gal targets (27, 30). Sertralinewas also shown to possess antitumor
activity (15, 16, 32). The antitumor activity was attributed to the
inhibition of the initiation of protein synthesis through its effects
on the mTOR pathway (15). It is not clear if translation is also a
target of sertraline in fungal cells, as homologs of certain relevant
factors important for translational regulation in mammals do not
exist in fungi. In addition to antifungal and antitumor activities,
sertraline has been shown to exert antiviral activity (14), antibac-
terial activity (19, 20), antiparasite activity (23), and spermicidal
activity (10). The antiproliferation activity of sertraline against
evolutionarily diverse organisms indicates its interference with
some fundamental processes. Based on our genetic screen and in
vitro translation assays using fungal cell extracts, we demonstrate
here that sertraline indeed inhibits protein synthesis in fungi.
Thus, together with previous studies, our results indicate that the
broad antiproliferation activity of sertraline might be attributable
to its interference with translation.
MATERIALS AND METHODS
Strains and media. The strains used in this study are listed in Table S1 in
the supplemental material. All yeast strains were maintained on yeast
extract-peptone-dextrose (YPD) medium. Drug disk diffusion and mi-
crodilution assays were performed using RPMI 1640 medium buffered
withMOPS (morpholinepropanesulfonic acid) according to the standard
protocol of CLSI.
Compounds and animals. Sertraline hydrochloride was dissolved in
dimethyl sulfoxide (DMSO) at a stock concentration of 20 mg/ml. The
drug was diluted with water or with appropriate media to the indicated
working concentrations in the in vitro studies. For animal studies, sertra-
line was dissolved in a 0.9 volume of water first, and then a 0.1 volume of
10 phosphate-buffered saline (PBS) stock solution was added. Flucona-
zole was dissolved at a stock concentration of 2 mg/ml in water and was
diluted by water or appropriate media in the in vitro studies. Fluconazole
was dissolved in 1 PBS buffer at 3 mg/ml for the animal studies. Female
A/J mice (10 to 12 weeks old) were purchased from Charles River (Wil-
mington, MA). Drug solutions for animal studies were freshly prepared
before daily injection.
In vitro study of antifungal activity.The drug disk diffusion assaywas
independently performed four times as previously described (40). The
microdilution assaywas performed according to theCLSI standard except
that cells were incubated at 37°C to mimic host conditions. The initial
inocula of fungal cells ranged from 1,500 to 2,000 cells/ml. Drugs were
added by calculating the desired dose as indicated. TheMICswere defined
by comparing the growth of the treated samples after 48 h of incubation
for Cryptococcus strains or 24 h of incubation for Candida strains versus
the no-drug control via measuring the absorbance at 600 nm. The mini-
mum fungicidal concentrations (MFCs) were defined as those at which at
least 99% of cells were killed compared to the original inocula. The num-
ber of viable cells was determined by plating the suspension on drug-free
solid media and then measuring CFU.
The interaction between sertraline (SRT) and fluconazole (FLC) was
quantified by the fractional fungicidal concentration index (FFCI) as fol-
lows: FFCI [FLC]/MFCFLC [PMB]/MFCSRT, where PMB represents
polymyxin B, MFCFLC and MFCSRT represent the concentrations of flu-
conazole and sertraline used alone, respectively, and [FLC] and [SRT]
represent the concentrations at which fluconazole and sertraline in com-
bination killed at least 99% of cells compared to the original inocula.
When MFC was not achieved (“” was used in these cases), the concen-
tration 2 that of the highest concentration tested was used for the FFCI
calculation. For the interaction of sertraline and fluconazole against Can-
dida strains, the status of cell proliferation was measured by the absor-
bance at 600 nm and is quantitatively displayed using gradations of color.
In vivo model of systemic cryptococcosis. Mice were assigned to 4
treatment groups: control (PBS), fluconazole, sertraline, and the drug
combination. All treatments, including the PBS control, were given intra-
peritoneally. The mice of the sertraline and the drug combination groups
were treated with sertraline at a dose of 15mg/kg of body weight/day for 7
days before Cryptococcus infection. All the mice were intravenously chal-
lenged with 1.0 104 H99 cells. The sertraline treatment was continued.
The fluconazole treatment at the dose of 15 mg/kg/day and treatment of
the drug combination group were initiated after 24 h of infection. All the
drug treatments continued for 3 consecutive days after infection, and the
mice were sacrificed. Brains, kidneys, and spleens of mice were harvested
and homogenized. Suspensions were serial diluted (10), plated onto
YPD agar, and incubated for another 2 days such that the colonies became
visible in order to calculate CFU. Animals were weighed daily and moni-
tored twice a day for disease progression and potential severe side effects,
including weight loss, gait changes, labored breaths, or fur ruffling. The
animal experiments were carried out in strict accordance with the recom-
mendations in theGuide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Texas
A&MUniversity Institutional Animal Care and Use Committee (IACUC;
animal protocol permit 2011-22).
The Saccharomyces cerevisiae gene deletion mutant screen for ser-
traline-resistant or sertraline-sensitive mutants. In the initial screen,
organisms from the genome deletionmutant collection were replicated in
96-well plates on RPMI agarmedium and onRPMI agarmediumwith the
addition of sertraline at 4g/ml and 6g/ml for the selection of sensitive
and resistant strains, respectively. After 2 days of incubation, about 300
strains with visually detectable differences in colony growth (representing
those that were either more sensitive or more resistant) were selected.
These selected strains were streaked onto medium for individual colonies
and tested through two additional rounds of experiments to exclude is-
sues of contamination during replication or storage. In total, 89 resistant
mutants and 33 sensitive mutants were selected. The mutations in several
of the most resistant and sensitive strains were confirmed by PCR.
In vitro translation assay. Cryptococcus H99 cells from an overnight
culture were inoculated into 2 liters of YPDmedium to an optical density
at 600 nm (OD600) of 0.05. The culture was incubated at 30°C with shak-
ing for approximately 10 more hours to reach an optical density of 2. At
this stage, the cells were collected, washed, and resuspended using the
same procedure as previously described for the preparation of yeast cell
extract (36). The resuspended cells were dripped directly into liquid ni-
trogen by using a sterile Pasteur pipette to form small ice beads. Frozen
cell beads were transferred into prechilled grinding vials of a Spex Sam-
plePrep 6850 Freezer/Mill and powdered in the liquid nitrogen-filled tub
using a setting consisting of 10min of precooling followed by three 2-min
grind cycles with 1 min of recooling between cycles. The powdered cells
were transferred to prechilled 50-ml polycarbonate centrifuge tubes, al-
lowed to thawon ice, and then centrifuged at 4°C for 15min at 16,000 rpm
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in an SS34 rotor. The supernatant was carefully collected with a sterile
Pasteur pipette, avoiding both the pellet and the fatty upper layer, and
placed in a fresh 15-ml conical tube that was maintained on ice. Small
molecules were removed from the extract by chromatography through
Sephadex G-25 superfine columns (36).
Capped, polyadenylated RNA encoding the firefly luciferase was syn-
thesized using T7 RNA polymerase from a plasmid template (pPQ101;
previously named pHLucNFS4 [33, 36]) linearized with EcoRI (for
polyadenylated RNA) or XbaI (for nonpolyadenylated RNA). Uncapped
RNA transcripts were also synthesized using the same procedure by omit-
ting the cap analog. The yield of RNA was quantified using Image-
QuantTL software and ethidium bromide-stained agarose gels by com-
parison to standard markers with known masses. Gel images were
acquired with a GE Typhoon Trio phosphorimager.
The in vitro translation reactionmixtures (10l; programmedwith 60
ng of template RNA) were incubated at 26°C for 40 min as described
previously (36). The reaction mixtures prepared in Cryptococcus extract
contained 110 mM KOAc, 35 mM HEPES-KOH (pH 7.6), 2.6 mM
Mg(OAc)2, and 10 M each amino acid. Translation reactions were
stopped by adding passive lysis buffer (Promega) for a final 1 concen-
tration. Firefly luciferase activity was determined using a luciferase assay
system (Promega) andmeasured with a Perkin Elmer Victor3Vmultilabel
counter. Where 5 Ci of [35S]Met (MP Biomedical) (1,000 Ci/mmol)
was used to label the translation products, the translation reaction mix-
tures contained 10 M each amino acid except methionine. Translation
reactions were stopped by adding sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) loading buffer (Invitrogen) for a final 1
concentration. [35S]Met-labeled translation products were analyzed on
SDS-PAGE gels and visualized using a GE Typhoon Trio phosphor-
imager.
RESULTS
Sertraline is potently fungicidal against various Cryptococcus
isolates in vitro. In our previous screen of the Johns Hopkins
Clinical Compound Library composed of 1,514 drugs approved
by the FDAor by one ormore foreign governmental agencies (40),
we found that sertraline exhibited a modest inhibitory effect on
Aspergillus nidulans. We investigated the activity of this antide-
pressant against Cryptococcus, given the brain involvement of
cryptococcal infections and the psychotropic property of this
drug. Sertraline displayed high potency against H99, a clinical and
referenceCryptococcus strain. TheMIC90 againstH99was approx-
imately 6g/ml (Table 1), which is much lower than the reported
MICs against many other fungal strains of Candida or Aspergillus
species (12, 13).
To determine whether sertraline is fungistatic or fungicidal, we
performed a comparative time course assay of cell viability in the
presence of sertraline and the commonly used fungistatic drug
fluconazole.We culturedCryptococcusH99 cells inRPMImedium
or in PBS buffer to represent rapidly proliferative or quiescent
cells, respectively. These cells were treated with no drug, sertraline
alone, fluconazole alone, or a combination of sertraline and flu-
conazole. At different time points, aliquots of cell suspensions
were spread onto drug-free solid medium to determine the num-
ber of viable cells by measuring the CFU. In RPMI medium, the
number of viable cryptococcal cells started to decrease at as early
as 2 h in the presence of sertraline compared to the no-drug con-
trol; there were no viable fungal cells in the presence of sertraline
TABLE 1 Sertraline, alone or with fluconazole, is potent against diverse Cryptococcus isolates
Strain
Serotype
(sourcea)
Geographic
origin
SRT FLC
SRT–FLC
MFCsc FFCIdMIC90
b MFCc MIC90
b MFCc
H99 A (C) North America 6 10 1 8 2–2 0.45
C45 A (C) North America 2 6 2 6 1–2 0.50
A7-35-23 A (E) North America 3 10 4 64 4–4 0.43
C23 A (C) North America 5 8 8 64 2–8 0.38
Bt31 A (C) Africa 4 8 12 32 4–8 0.63
Bt81 A (C) Africa 5 8 12 64 2–16 0.38
92BC2-45 A (C) Europe 6 10 4 64 6–32 0.85
92BC1-52 A (C) Europe 3 8 3 64 2–4 0.31
98BC1-86 A (C) Europe 5 8 2 32 2–16 0.75
A2-102-5 A (E) North America 5 8 16 32 4–8 0.75
123.96 A (C) North America 4 8 8 64 4–16 0.63
Bt50 A (C) Africa 6 10 16 64 4–32 0.65
163.99 A (C) North America 4 6 6 64 2–32 0.58
UA 1993 A (C) Europe 5 8 2 6 2–2 0.54
JEC21 D (L) North America 2 6 1 4 1–2 0.83
3-10 D (E) North America 3 10 4 64 2–8 0.26
3-17 D (E) North America 4 8 2 64 2–4 0.31
93BC2-52 D (C) Europe 3 8 4 32 1–8 0.38
99BC1-40 D (C) Europe 4 8 3 32 2–4 0.38
UA 491 D (C) Europe 4 8 2 8 2–2 0.50
XL1495 AD hybrid (L) North America 4 8 3 8 2–4 0.75
UM4 AD hybrid (N) Europe 4 10 6 64 4–16 0.53
92C AD hybrid (N) Europe 4 10 4 64 6–32 0.85
VPCI 87 C. gattii (E) North America 4 10 6 64 2–8 0.33
a (C), clinical strain; (E), environmental strain; (L), laboratory strain; (N), not available.
b MIC90 (shown in micrograms per milliliter), the lowest drug concentration that resulted in a 90% decrease in absorbance.
c MFC (minimal fungicidal concentration) (shown in micrograms per milliliter), the lowest concentration at which at least 99% of cells were killed compared to the original
inoculums. When fluconazole was used alone, the MFC was sometimes not achieved in the dose range tested, as indicated by “.”
d FFCI, fractional fungicidal concentration index. FFCIs 0.5, drug effects were synergistic; FFCIs between 0.5 and 1.0, drug effects were additive; FFCIs between 1.0 and 2.0, drug
effects were indifferent; FFCIs 2.0, drug effects were antagonistic (4).
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after 48 h of incubation (Fig. 1A). Sertraline was modestly more
effective than fluconazole under these conditions (Fig. 1A). The
drug combination showed the highest efficiency in clearing the
yeast cells (Fig. 1A). Similarly, H99 cells in PBS buffer were rapidly
cleared by sertraline (within 4 h after inoculation), indicating that
sertraline is fungicidal and is potent against Cryptococcus cells re-
gardless of whether cells are growing or not (Fig. 1B). In sharp
contrast, fluconazole showed no effect on the viability of the fun-
gal cells in PBS buffer (Fig. 1B). The lack of killing effect of flu-
conazole on quiescent fungal cells is consistent with the classifica-
tion of fluconazole as a fungistatic drug: that is, it is effective in
inhibiting fungal cell proliferation but ineffective in destroying
cells that are not actively growing. The fungicidal effect of sertra-
line is not specific toCryptococcus, as sertraline also killed S. cerevi-
siaeBY4742 cells regardless ofwhether theywere growing inRPMI
medium or quiescent in PBS buffer (see Fig. S1 in the supplemen-
tal material). These results indicate that sertraline is able to kill
fungal cells independently of whether they are proliferating.
To examinewhether the susceptibility to sertraline is specific to
the H99 strain or is a general trait of Cryptococcus, we further
tested 23 genetically and phenotypically distinct Cryptococcus
strains, including 13 serotype A (this serotype accounts for 95%of
clinical cryptococcosis cases), 6 serotype D (serotype D represents
fewer than 5% of clinical cases of cryptococcosis), 3 serotype A-
serotype D hybrids, and 1 C. gattii strain (Table 1). These strains
are clinical or environmental isolates from North America, Eu-
rope, or Africa. The MICs of sertraline were determined by the
microdilution assay according to the CLSI standard. Compared to
thewide range of inhibitory concentrations of fluconazole (from1
to64 g/ml), all of these strains are very sensitive to sertraline,
with a surprisingly narrow spectrum of inhibitory concentrations
(10 g/ml) (Table 1). Notably, there is no correlation between
the levels of susceptibility to fluconazole and to sertraline among
these strains, indicating that there is no cross-resistance between
sertraline and fluconazole. Thus, it is unlikely that these two drugs
share common mechanisms of action. These results imply the
general susceptibility ofCryptococcus strains to sertraline irrespec-
tive of their level of susceptibility to fluconazole.
Sertraline interacts synergistically or additively with flu-
conazole against Cryptococcus in vitro. As fluconazole is the
most commonly used antifungal in cryptococcosis treatment,
drugs that can act additively or synergistically with fluconazole are
more likely to be used clinically. In the time course assay described
above, we observed that the combination of sertraline and flu-
conazole accelerated the clearance of proliferative Cryptococcus
cells (Fig. 1A). To determine the interaction between sertraline
and fluconazole against Cryptococcus, we compared the suscepti-
bility of the 24 isolates to a combination of these drugs with their
susceptibility to each drug alone using the disk diffusion halo as-
say. For all the strains tested, halos formed near disks containing
the drug combination were larger and clearer than those formed
near disks containing either fluconazole or sertraline alone (data
not shown, but see Fig. S2 in the supplemental material). The
results indicate possible synergistic or additive interactions be-
tween sertraline and fluconazole against Cryptococcus.
We next quantified the interaction between sertraline and flu-
conazole against Cryptococcus by using a microdilution assay to
determine the fractional fungicidal concentration index (FFCI).
Sertraline increases the antifungal activity of fluconazole against
all the tested Cryptococcus strains, demonstrating a synergistic
(FFCI 0.5) or additive (FFCI between 0.5 and 1.0) (4) effect of
the combination of the two drugs (Table 1). This is consistent with
the results obtained by the disk diffusionmethod. Considering the
divergence of the genetic backgrounds of the tested strains, these
observations suggest the possibility that the combination of ser-
traline and fluconazole could be more effective at clearing differ-
ent Cryptococcus isolates in cases of mammalian cryptococcosis.
Sertraline alone or in combinationwith fluconazole displays
antifungal activity in a murine model of systemic cryptococco-
sis.Asdescribed earlier, sertraline exerts anti-Cryptococcus activity
alone or in combination with fluconazole in vitro. To determine
the efficacy of sertraline or its combination with fluconazole in
vivo, we adopted a murine model of systemic cryptococcosis. We
chose the intravenous model of cryptococcosis here, because our
pilot experiments showed that organ fungal burden displayed rel-
atively low variations among individual animals. To examine the
drug efficacy in this model, we assignedmice into four groups: the
control (PBS) group, the fluconazole treatment group, the sertra-
line treatment group, and the group receiving a drug combina-
tion. Given that it takes at least 5 to 7 days for sertraline to reach a
steady state in the mouse brain (8), mice of the sertraline group
and the drug combination group were given a 7-day pretreatment
of sertraline prior to the infection by the Cryptococcus H99 refer-
ence strain. Based on previous studies, the serum level of sertraline
in these animals was likely to be too low (55 to 250 ng/ml [34]) to
FIG 1 Sertraline is fungicidal against both proliferative and quiescent Cryp-
tococcus cells. (A) H99 cells were inoculated into RPMI media and cultured
without any drug (control) or in the presence of fluconazole (FLC; 8g/ml) or
sertraline (SRT; 10 g/ml) or a combination of these two drugs. At the indi-
cated time points, aliquots of cell suspensionswere transferred and plated onto
drug-free agar medium to determine CFU after 2 more days of incubation.
Fungal cells proliferated rapidly in the absence of any drugs, but they were
gradually cleared with any of the drug treatments. (B) H99 cells were inocu-
lated into PBS buffer and cultured without any drug (control) or in the pres-
ence of fluconazole (8g/ml) or sertraline (8g/ml) or a combination of these
two drugs. At the indicated time points, aliquots of cell suspensions were
transferred and plated on drug-free medium to determine CFU after 2 more
days of incubation. Fungal cells in PBS maintained viability during the tested
period.
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exert any growth-inhibitory effect on the fungal cells initially in-
oculated into the bloodstream. Fluconazole treatment was initi-
ated at 1 day postinfection (dpi 1) in both the treatment group
administered fluconazole alone and the drug combination treat-
ment group. Such treatment was continued for 3 consecutive
days. The animals were sacrificed at dpi 4; their brain, kidney, and
spleen tissues were homogenized and the fungal burdens of these
organs were determined by measuring CFU. As shown in Fig. 2,
the treatment with sertraline alone reduced the fungal burden in
the brain (P  0.05), with its efficacy comparable with that of
fluconazole. Sertraline also reduced fungal burden in kidney,
while fluconazole showed no apparent effect. Sertraline appeared
to have amodest effect on fungal burden in spleen, but such effect
was not statistically significant. The differences in the levels of
drug efficacy for the three organs examined may reflect variations
of drug concentrations at these organs. Importantly, the treatment
with the combination of sertraline and fluconazole displayed the
most potent efficacy in reducing fungal burden of all three organs
examined (Fig. 2). Therefore, the data demonstrate that sertraline
alone is efficacious against cryptococcosis and that the combina-
tion of sertraline with fluconazole is a more effective treatment
than either drug alone due to their strong synergy in vivo.
Sertraline antagonizes the growth-inhibitory effect of flu-
conazole onmanyCandida strains. To examine if the potency of
sertraline alone or in combination with fluconazole can be ex-
tended toCandida species, we tested theMICs of sertraline against
six strains that represent six different Candida spp.: C. albicans
SC5314,C. glabrata PAT2ISO3,C. kruseiDUMC132.91,C. parap-
silosis MMRL1594, C. tropicalis MMRL2017, and C. lusitaniae
2-367. The MIC90s ranged from 12 to 24 g/ml (Table 2), which
are considerably higher than the MICs against Cryptococcus but
are consistentwith previous studies (13, 37). TheseMIC values are
higher than the achievable blood or even organ levels of sertraline.
In striking contrast to the results obtained with Cryptococcus,
sertraline had a significant antagonistic impact on the inhibitory
effect of fluconazole for the majority of the tested Candida stains
in vitro (Fig. 3). For example, 1-day incubation with fluconazole
alone was able to effectively inhibit the growth of the C. tropicalis
MMRL2017 strain at a concentration of 1.0g/ml. However, with
the addition of sertraline (1.0 to 6.0g/ml), fungal growth in the
presence of fluconazole not only recovered but actually became
more robust. The spectrum of the concentrations at which sertra-
line exerts an antagonistic effect with fluconazole unfortunately
falls in the clinically relevant range. Similar antagonistic interac-
tions between sertraline and fluconazole were also observed
among three other Candida strains: C. albicans SC5314, C.
glabrata PAT2ISO3, and C. parapsilosisMMRL1594 (Fig. 3). Ser-
traline did not decrease the inhibitory effect of fluconazole on C.
lusitaniae 2-367 or onC. kruseiDUMC132 (Fig. 3). Although syn-
ergistic or additive interactions between sertraline and flucona-
zole were reported in studies of some Candida strains (30), antag-
onistic interactions between fluconazole and sertraline are
commonly observed among Candida and Aspergillus strains (this
study and reference 7).
Sertraline interferes with translation in fungal cells. The
broad antiproliferation activity of sertraline against many organ-
isms indicates that the mechanism underlying its fungicidal activ-
ity may involve some fundamental cellular processes. To identify
the potential fungalmolecules andprocesses affected by sertraline,
we screened the whole-genome deletion collection of S. cerevisiae
for sertraline-sensitive or sertraline-resistant mutants. This mu-
tant collection set is composed of a nonessential gene deletion set
in a haploid background and an essential gene deletion in a
heterozygous diploid background (35). After one round of initial
TABLE 2 Sertraline is less potent against Candida strains
Strain MIC90 (g/ml) MIC100
a (g/ml)
Candida albicans SC5314 32 48
Candida glabrata PAT2ISO3 12 16
Candida krusei DUMC132.91 12 16
Candida parapsilosisMMRL1594 24 24
Candida tropicalisMMRL2017 24 32
Candida lusitaniae 2-367 8 24
a MIC100, the lowest drug concentration that resulted in a 100% decrease in
absorbance.
FIG 2 Sertraline reduces the fungal burden alone or in combination with
fluconazole in vivo. Brains (A), kidneys (B) and spleens (C) of mice from
different treatment groups were dissected and homogenized. The suspensions
were diluted serially, and the fungal burden was determined by calculating
CFU. Sertraline alone significantly reduced the brain and the kidney fungal
burden,while the drug combination reduced the fungal burden significantly in
all three organs. *, P  0.05; **, P  0.01; ***, P  0.001. In brain, the drug
combination displayed higher potency compared to either fluconazole or ser-
traline alone (both P  0.05). The efficacy of the drug combination is also
superior to that of fluconazole alone in kidney (P 0.001) or that of sertraline
alone in spleen (P 0.001).
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screening and two rounds of additional screening to confirm the
selected phenotype, 88 resistant and 36 sensitive strains were iden-
tified (see Table S2 in the supplemental material). Gene ontology
analyses indicated that these genes are enriched for those with
roles in intracellular vesicle transport andmembrane organization
(Fig. 4), which is consistent with the findings of two recent studies
of the effects of sertraline on yeast (27, 30).
Interestingly, genes related to protein synthesis are highly en-
riched in the resistant group; the most sensitive mutant selected
from our screen was strain 	tif3, in which an important transla-
tion initiation factor Tif3 was disrupted. Since previous studies in
mammalian cells have indicated that sertraline inhibits translation
initiation (15), these data indicated that it was possible that ser-
traline also disrupts translation in fungi.
Sertraline inhibits translation in aCryptococcus cell-free sys-
tem. To determine the effect of sertraline on translation in Cryp-
tococcus, we performed in vitro translation assays. In these assays,
the luciferase mRNA was used as the template and the translation
machinery was provided by the cell extract obtained from C. neo-
formans strain H99. As expected, translation in theseCryptococcus
cell extracts was synergistically dependent on themRNA 5= termi-
nal cap and 3= terminal poly(A) tail, as with Saccharomyces cell
extract (Fig. 5A) and Neurospora crassa cell extract (33, 36). This
result verified that the Cryptococcus in vitro translation system
faithfully recapitulated the dependence of cap and poly(A) for
translation.
The effects of sertraline on translation of cap and poly(A) lu-
ciferase mRNA were assessed by measurement of both (i) the en-
zymatic activity of the luciferase produced by the in vitro transla-
tion and (ii) the level of [35S] methionine incorporation into the
luciferase polypeptide produced. We found that sertraline inhib-
ited the translation efficiency in a dose-dependent manner using
both detectionmethods (Fig. 5B and C). Luciferase enzyme activ-
ity dropped 50% compared to the control when the concentration
of sertraline was increased to 0.1 mM (30.6 g/ml). No enzyme
activity above the background was detected in the presence of
sertraline at 0.4 mM (122.4 g/ml). The decrease in luciferase
enzyme activity in the presence of sertraline was not due to direct
interference of sertralinewith the enzymatic activity of the synthe-
sized luciferase, since, based on this measurement, addition of
sertraline into the cell extract after translation was completed did
not alter enzyme activity (Fig. 5B). The [35S]methionine incorpo-
ration assay showed that sertraline affected the yield of luciferase
polypeptide synthesized in this cell extract (Fig. 5C). Protein syn-
thesis was also affected by sertraline in fungal extracts derived
from the yeast S. cerevisiae and the filamentous fungus N. crassa,
although higher concentrations of sertraline were required to
achieve a similar level of inhibition (see Fig. S3 in the supplemen-
FIG 3 Antagonistic effects between sertraline and fluconazole among Candida strains. Six Candida strains, C. albicans SC5314, C. glabrata PAT2ISO3, C. krusei
DUMC132.91, C. parapsilosisMMRL1594, C. tropicalisMMRL2017, and C. lusitaniae 2-367, were incubated in RPMI media with the indicated drug treatment.
Gradients in columns represent sertraline (shown in micrograms per milliliter); gradients in rows represent fluconazole (shown in micrograms per milliliter).
The scale of the fluconazole concentrations was determined based on a previous study (40). Growth was measured by absorbance at 600 nm after 24 h of
incubation. Green indicates fungal growth, and black indicates the lack of fungal growth.
FIG 4 Gene ontology analysis of the S. cerevisiae genes involved in sertraline tolerance or susceptibility. Gene ontology (GO) terms for annotated S. cerevisiae
genes involved in sertraline resistance (A) or susceptibility (B) were extracted from the GO database and sorted into the immediate subcategories for molecular
functions and biological processes. See Table S2 in the supplemental material for the detailed gene list.
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talmaterial). In contrast, fluconazole, which is known to target the
enzyme Erg11 in the ergosterol biosynthetic pathway, did not
show any inhibitory effect on protein synthesis in a similar con-
centration range in such assays (see Fig. S4 in the supplemental
material). These data obtained in cell-free translation systems us-
ing fungal extracts show that sertraline interferes with fungal pro-
tein synthesis.
DISCUSSION
Sertraline offers a promising option for the treatment of cryp-
tococcosis, especially cryptococcal meningitis.Here we provide
evidence for the potent anticryptococcal activity of the antidepres-
sant sertraline both in vitro and in vivo. Given the difficulties in
developing antifungal drugs de novo, recent studies have explored
existing clinical compounds for potential use as antifungals (39).
Existing pharmaceutical and safety information concerning the
use of these drugs in animals or in humans could greatly accelerate
the investigation into their clinical use as antifungals. Consistent
with the safety profile of sertraline for long-term use in patients,
we did not observe any severe side effects due to sertraline admin-
istration during the treatment process in the animal studies pre-
sented here. Previous studies also showed the safety of sertraline
administration in mice with a similar daily dose but for a much
longer period of time (25).
The discovery that sertraline has anticryptococcal activity of-
fers the potential for an additional choice for treating cryptococ-
cosis. Our tests of 24 diverse Cryptococcus strains indicate a uni-
formly high sensitivity of this fungus to sertraline relative to other
fungal species tested. Compared to fluconazole, sertraline showed
a much narrower range of inhibitory concentrations against these
diverse Cryptococcus isolates (Table 1), suggesting a lower proba-
bility of naturally occurring resistance to sertraline in existing
Cryptococcus populations. The fungicidal nature of sertraline and
its synergy with fluconazole against Cryptococcus, as previously
observed in vitro (21) and in vivo in an insect model (30) and in
this study shown in a mammalian model, could potentially
shorten the duration of anticryptococcal therapy and reduce the
risk of emerging drug resistance. During latent infection or during
fluconazole treatment, Cryptococcus cells are likely dormant or
grow slowly. Given that even dormant cells need transcription and
translation (22), and that sertraline is capable of killing fungal cells
under quiescent conditions, it is reasonable to speculate that ser-
traline might be useful to clear latent cryptococcal infections or to
kill residual fungal cells unharmed by the fluconazole treatment.
This could be tested by further investigation.
It is worth mentioning that we did not observe any differences
in survival in any of the treatment groups (including the flucona-
zole-treated groups). This is most likely due to the rapid disease
progression in thismodel. The A/Jmouse used in this study is very
susceptible to Cryptococcus infections, and H99 is one of the most
virulent clinical isolates of Cryptococcus (38). We tried different
inocula of the fungal cells (1  103, 1  104, and 1  105 cells/
mouse) in this intravenous infection model and found that a 10-
fold decrease in the inoculumprolonged survival for an additional
1 to 2 days and that infected mice all succumbed to the diseases
within 8 days. We speculate that better protection against crypto-
coccosis by sertraline or the drug combination might be observed
in other animal models or in humans, or if cryptococcosis is
caused by less virulent strains. Optimization of drug doses, the
route and frequency of drug administration, and the duration of
treatment warrants further investigation in order to assess the
treatment outcomes.
One of the most valuable aspects of sertraline as a potential
anticryptococcal drug is its superior ability to accumulate in the
CNS relative to other antifungals. This is particularly critical in the
treatment of cryptococcosis, given thatCryptococcus preferentially
proliferates in the brain. Consistent with our expectations, the in
vivo study presented here supports the hypothesis of the ability of
sertraline, either alone or in combination with fluconazole, to
reduce brain fungal burden.
Although sertraline demonstrates efficacy against cryptococ-
cosis comparable to that of fluconazole based on the data pre-
sented here, the potential application of this drug to treat mycoses
caused by fungal pathogens such as Candida or Aspergillus re-
quires further investigation. The commonly observed antagonis-
tic interaction between sertraline and fluconazole againstCandida
FIG 5 Sertraline inhibits translation in aCryptococcus cell-free system. The cell-free translation systemwas prepared as described inMaterials andMethods. (A)
The translation of luciferase in bothCryptococcus and Saccharomyces cell extracts is dependent on themRNA5= terminal cap, designatedC, and on the 3= terminal
poly(A) tail, designated A. The cap and poly(A) synergistically stimulate RNA translation in both cell-free systems. (B and C) Water, the solvent DMSO, or
sertraline in stock solutionwas added into reactionmixtures to reach the indicated concentrations. Luciferase protein synthesis by the cell-free translation system
was measured based on the relative light units arising from the enzymatic activity of luciferase (B) or the level of [35S]methionine incorporated into the
synthesized luciferase polypeptide (C). Both measurements showed that sertraline inhibited translation in a dose-dependent manner.
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and Aspergillus strains is particularly concerning (this study and
reference 7). It is possible that specific chemical modification of
sertraline could increase its efficacy against these other fungi and
abolish its antagonistic interaction with fluconazole. Such modi-
fications would increase its value in the battle against systemic
mycoses.
The antifungal mechanisms of sertraline. Sertraline displays
extremely broad antiproliferation activity against evolutionarily
diverse organisms (10, 12–15, 19, 20, 23). Recent studies indicate
the influence of sertraline on membrane stability or vesicle trans-
port in fungi (27, 30). The results of our S. cerevisiae mutant
screens are consistent with these discoveries. Our mutant screens
and the in vitro translation assays also indicated protein synthesis
as another process interfered with by sertraline. Our finding re-
garding the inhibitory effect of sertraline on translation is consis-
tent with a recent study on translation in tumor cells (15), even
though the implicated mammalian factors in the mTOR pathway
identified in that study, such as PDCD4 or REDD1, do not have
obvious homologs in fungi. Inhibition of translation could possi-
bly cause changes in other processes, as molecules involved in
protein trafficking andmembrane proteins were also significantly
enriched in our screen (Fig. 4; see also Table S2 in the supplemen-
tal material). Sertraline’s impact on translation might more
acutely affect protein synthesis from specific transcripts in Cryp-
tococcus important for growth such that it does not need to com-
pletely inhibit protein synthesis for its strong anticryptococcal ac-
tivity. Thus, while sertraline inhibits mammalian protein
synthesis, it may be that qualitative, not quantitative, differences
in sertraline’s effects on fungal protein synthesis are crucial for
sertraline’s antiproliferation activity.
The possibility of emergence of fungal resistance to sertraline
seems low based on the following observations. First, we noted
during our genetic screen that S. cerevisiae gene deletion mutants
selected for sertraline resistance showed an increase in MIC of
only up to 50% compared to the wild type. Second, our repeated
attempts to perform UV mutagenesis with S. cerevisiae and C.
neoformans failed to yield any resistant strains with sertraline
MICs greater than 14 g/ml. Third, all natural Cryptococcus
strains tested showed uniformly high sensitivity to sertraline. Such
observations are drastically different fromwhat is known for azole
drugs, as a more than 10- to 100-fold difference in fluconazole
susceptibilities can be easily observed in both clinical and labora-
tory settings. This feature, although making it rather challenging
to pinpoint the underlying fungicidal mechanisms of sertraline,
could be advantageous for its clinical application, as the possibility
of encountering sertraline-resistant Cryptococcus isolates and the
risk of developing fungal resistance during therapy would be low.
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